STOK insider buying and SEC filings, explained
Stoke Therapeutics, Inc. · CIK 1623526
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$1.5M
Planned sales (10b5-1)
$7.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 2, 2026 | Planned (10b5-1) | Jonathan Allan (General Counsel & Corp Sec) sold 627 shares at $26.33 ($17K), marked as a 10b5-1 plan trade. Holdings down 3% to 20,598 shares. | SEC filing Filed Oct 2, 2026, 5:37 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 1,051 shares at about $26.16 ($27K), marked as a 10b5-1 plan trade. Holdings down 5% to 19,059 shares. | SEC filing Filed Oct 2, 2026, 5:35 PM ET |
| Sep 1, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 5,545 shares at about $30.67 ($170K), marked as a 10b5-1 plan trade. Holdings down 22% to 20,110 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 18, 2026 | Sale | Jonathan Allan (General Counsel & Corp Sec) sold 2,861 shares at about $32.03 ($92K). Holdings down 12% to 21,225 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 18, 2026 |
| Aug 18, 2026 | Sale | Barry Ticho (Chief Medical Officer) sold 4,767 shares at about $32.03 ($153K). Holdings down 16% to 25,655 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 18, 2026 |
| Aug 18, 2026 | Sale | Edward M. MD Kaye (Director) sold 12,567 shares at about $32.03 ($403K). Holdings down 9% to 124,557 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 18, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 7,176 shares at about $29.04 ($208K), marked as a 10b5-1 plan trade. Holdings down 26% to 20,422 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 7,228 shares at about $32.66 ($236K), marked as a 10b5-1 plan trade. Holdings down 21% to 27,598 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 16, 2026 | Planned (10b5-1) | Jonathan Allan (General Counsel & Corp Sec) sold 1,457 shares at $29.95 ($44K), marked as a 10b5-1 plan trade. Holdings down 7% to 18,086 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 1,795 shares at $30.58 ($55K), marked as a 10b5-1 plan trade. Holdings down 5% to 34,826 shares. | SEC filing Filed Jun 3, 2026 |
| May 1, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 2,243 shares at $32.79 ($74K), marked as a 10b5-1 plan trade. Holdings down 6% to 36,621 shares. | SEC filing Filed May 5, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 1,838 shares at $32.66 ($60K), marked as a 10b5-1 plan trade. Holdings down 5% to 38,864 shares. | SEC filing Filed Apr 3, 2026 |
| Mar 20, 2026 | Planned (10b5-1) | Jonathan Allan (General Counsel & Corp Sec) sold 9,293 shares at about $33.69 ($313K), marked as a 10b5-1 plan trade. Holdings down 32% to 19,543 shares. | SEC filing Filed Mar 24, 2026 |
| Mar 17–18, 2026 | Sale | Jonathan Allan (General Counsel & Corp Sec) sold 8,895 shares between Mar 17 and Mar 18 at about $32.14 ($286K). Holdings down 24% to 28,836 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 14,311 shares between Mar 17 and Mar 19 at about $31.92 ($457K), marked as a 10b5-1 plan trade. Holdings down 26% to 40,702 shares. | SEC filing Filed Mar 19, 2026 |
| Mar 17–18, 2026 | Sale | Thomas Leggett (CFO) sold 4,578 shares between Mar 17 and Mar 18 at about $32.14 ($147K). Holdings down 31% to 10,172 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–18, 2026 | Sale | Jason Hoitt (Chief Patient Officer) sold 3,712 shares between Mar 17 and Mar 18 at about $32.14 ($119K). Holdings down 27% to 10,276 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Arthur A. Levin (Director) sold 605 shares at $36.80 ($22K), marked as a 10b5-1 plan trade. Holdings down 12% to 4,237 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | Adrian R. Krainer (Director) sold 33,243 shares at about $39.74 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 11% to 283,302 shares. | SEC filing Filed Mar 12, 2026 |
| Mar 10, 2026 | Planned (10b5-1) | Arthur Tzianabos (Chair and Director) sold 4,355 shares at about $40.00 ($174K), marked as a 10b5-1 plan trade. Holdings down 12% to 31,339 shares. | SEC filing Filed Mar 12, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Adrian R. Krainer (Director) sold 7,229 shares at about $39.66 ($287K), marked as a 10b5-1 plan trade. Holdings down 2% to 316,545 shares. | SEC filing Filed Mar 4, 2026 |
| Dec 8, 2025 | Planned (10b5-1) | Jonathan Allan (General Counsel & Corp Sec) sold 3,978 shares at about $32.28 ($128K), marked as a 10b5-1 plan trade. Holdings down 25% to 11,831 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 8, 2025 | Planned (10b5-1) | Edward M. MD Kaye (Director) sold 13,430 shares at about $32.27 ($433K), marked as a 10b5-1 plan trade. Holdings down 21% to 49,124 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 4–5, 2025 | Planned (10b5-1) | Jonathan Allan (General Counsel & Corp Sec) sold 9,803 shares between Dec 4, 2025 and Dec 5, 2025 at about $31.25 ($306K), marked as a 10b5-1 plan trade. Holdings down 38% to 15,809 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 4–5, 2025 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 5,358 shares between Dec 4, 2025 and Dec 5, 2025 at about $31.19 ($167K), marked as a 10b5-1 plan trade. Holdings down 21% to 19,798 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 4–5, 2025 | Planned (10b5-1) | Edward M. MD Kaye (Director) sold 15,001 shares between Dec 4, 2025 and Dec 5, 2025 at about $31.13 ($467K), marked as a 10b5-1 plan trade. Holdings down 19% to 62,554 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 2–3, 2025 | Sale | Jonathan Allan (General Counsel & Corp Sec) sold 4,576 shares between Dec 2, 2025 and Dec 3, 2025 at about $30.22 ($138K). Holdings down 19% to 19,612 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 3, 2025 |
| Dec 2–3, 2025 | Sale | Barry Ticho (Chief Medical Officer) sold 4,020 shares between Dec 2, 2025 and Dec 3, 2025 at about $30.22 ($121K). Holdings down 21% to 15,156 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 3, 2025 |
| Dec 2–3, 2025 | Sale | Edward M. MD Kaye (Director) sold 2,136 shares between Dec 2, 2025 and Dec 3, 2025 at about $30.22 ($65K). Holdings down 4% to 51,305 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 3, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Adrian R. Krainer (Director) sold 40,472 shares at about $29.72 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 11% to 323,774 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 14, 2025 | Planned (10b5-1) | Adrian R. Krainer (Director) sold 40,472 shares at about $26.98 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 10% to 364,246 shares. | SEC filing Filed Nov 18, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Barry Ticho (Chief Medical Officer) sold 5,931 shares at about $25.72 ($153K), marked as a 10b5-1 plan trade. Holdings down 45% to 7,195 shares. | SEC filing Filed Nov 5, 2025 |
33 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow STOK in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.